Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study

HIGHLIGHTS

• who: Frida Bju00f6rk Gunnarsdottir from the at Lund University (Dnr, ) and conducted in accordance with the Declaration of HelsinkiWritten informed consent was obtained from all patients prior to study inclusion. The cohort constitutes , patients with newly diagnosed MBC, planned for first-line systemic treatment and has previously been described in detail [19-21]. Serum samples were taken at baseline (before start of systemic therapy) and out of the , patients, serum samples were lost or excluded (for , patients have published the research work: Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.